Dr. Kim is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
243 Charles St
Boston, MA 02114Phone+1 617-573-3367
Education & Training
Massachusetts Eye and Ear Infirmary/Harvard Medical SchoolResidency, Ophthalmology, 2001
Harvard Medical SchoolClass of 1997
Certifications & Licensure
MA State Medical License 2001 - 2026- American Board of Ophthalmology Ophthalmology
Awards, Honors, & Recognition
- Super Doctor SuperDoctors.com
- Fellow (FAAO) American Academy of Ophthalmology
Clinical Trials
- Ranibizumab in Combination With Proton Beam Irradiation for Choroidal Melanoma Start of enrollment: 2008 Jun 01
- Intravitreal Bevacizumab vs.Combination Therapy for CNV Due to Other Than AMD Start of enrollment: 2010 Aug 01
- Dexamethasone Implant for Retinal Detachment in Uveal Melanoma Start of enrollment: 2018 Apr 16
- Join now to see all
Publications & Presentations
PubMed
- Confirmatory Cytopathology and Potential Impact on the Predictive Value of Gene Expression Profiling in Patients With Uveal Melanoma.Anne Marie Lane, Caleb D Hartley, Ronan McCarthy, Ashley Go, Evangelos S Gragoudas
Journal of Vitreoretinal Diseases. 2024-12-13 - Visual Outcomes after Proton Therapy for Recurrent Uveal Melanoma.Megan S Steinkerchner, Caleb D Hartley, Anne M Lane, Frances Wu, Evangelos S Gragoudas
Ophthalmology. Retina. 2024-11-01 - 1 citationsOverloading And unpacKing (OAK) - droplet-based combinatorial indexing for ultra-high throughput single-cell multiomic profiling.Bing Wu, Hayley M Bennett, Xin Ye, Akshayalakshmi Sridhar, Celine Eidenschenk
Nature Communications. 2024-10-23
Journal Articles
- Survival Rates in Patients After Treatment for Metastasis from Uveal MelanomaIvana K Kim, Evangelos S Gragoudas, JAMA
Press Mentions
Aura Biosciences Reports Third Quarter 2024 Financial Results and Business HighlightsNovember 12th, 2024- Clearside Biomedical Announces Positive Data on CLS-AX OASIS Clinical Trial and Use of SCS MicroinjectorFebruary 21st, 2023
- Aura Biosciences Announces Positive Interim Phase 2 Data of Belzupacap Sarotalocan for Treatment of Early-Stage Choroidal MelanomaFebruary 16th, 2023
- Join now to see all
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
